We are seeking your comments on the draft SIGN evidence-based guideline on Management of cutaneous melanoma, developed by a multidisciplinary group chaired by Dr Ewan Brown, Consultant in Medical Oncology, Edinburgh Cancer Centre, as part of our open consultation.
The guideline is a selective update of SIGN 72. In a selective update SIGN identifies key areas from an existing guideline to update and reviews newly published evidence to make recommendations relevant and practical for the current service needs. Newer evidence that would not substantially change an existing recommendation has not been reviewed. Sections of SIGN 72 that are still valid current practice have been retained. The key clinical questions used to inform the update of the guideline are listed at the back of the document and sections that have been updated are outlined in section 1.2.3.
We are seeking your view on the comprehensiveness and accuracy of interpretation of the evidence base supporting the recommendations in the sections of the guideline that have been revised. Comments on the style or presentation of the draft would also be welcome.
Please include key references to support your comments on this evidence-based guideline wherever possible.
